摘要
在过去的几年中,已有研究成功通过 gammaretro病毒或者慢病毒的载体系统转移了治疗性基因。这证明了携带这些基因的病毒可以作为治疗一系列遗传疾病的可选方法。基因疗法已批准的I / II期临床试验的数量,特别是罕见病的,正稳步上升,但要成为被广泛接受的治疗方法整体上仍然存在众多障碍。在临床医生和基础科研人员的努力下,我们对基因治疗的可行性和生物安全性的认识提高到了新的水平。然而,尽管已产生了大量的临床和临床前安全性数据,我们还缺乏足够强有力的检测,以评估预测在临床基因治疗中将遇到的确切水平。插入诱变是使用整合载体永久改造细胞时的主要问题之一;而在早期基因治疗试验中与基因毒性相关的不良事件的发生,都抑制了基因治疗领域的进一步发展。在本综述中, 我们总结了已报道的使用整合载体进行基因治疗的临床试验中发生的不良事件,全面概述了其中共有的基本原则和潜在的共同因素。此外,我们总结了在临床前水平下可用以评估遗传毒性的系统,并揭示了在临床角度下解释这些毒性研究结果时影响这些试验预测值的问题。在综述的最后一节,我们简要介绍了未来的发展趋势,以及未来趋势如何能提高采用整合载体技术的基因疗法的安全性,并使其发展到一个新的水平。
关键词: 临床试验、基因疗法、插入诱变、慢病毒载体的、临床前的、逆转录病毒的、安全性。
Current Gene Therapy
Title:Safety of Gene Therapy: New Insights to a Puzzling Case
Volume: 14 Issue: 6
Author(s): Michael Rothe, Axel Schambach and Luca Biasco
Affiliation:
关键词: 临床试验、基因疗法、插入诱变、慢病毒载体的、临床前的、逆转录病毒的、安全性。
摘要: Over the last few years, the transfer of therapeutic genes via gammaretro- or lentiviral vector systems has proven its virtue as an alternative treatment for a series of genetic disorders. The number of approved phase I/II clinical trials, especially for rare diseases, is steadily increasing, but the overall hurdles to become a broadly acceptable therapy remain numerous. The efforts by clinicians and basic scientists have tremendously improved the knowledge available about feasibility and biosafety of gene therapy. Nonetheless, despite the generation of a plethora of clinical and preclinical safety data, we still lack sufficiently powerful assays to predictively assess the exact levels of toxicity that might be observed in any given clinical gene therapy. Insertional mutagenesis is one of the major concerns when using integrating vectors for permanent cell modification, and the occurrence of adverse events related to genotoxicity, in early gene therapy trials, has refrained the field of gene therapy from emerging further. In this review, we provided a comprehensive overview on the basic principles and potential co-factors concurring in the generation of adverse events reported in gene therapy clinical trials using integrating vectors. Additionally, we summarized the available systems to assess genotoxicity at the preclinical level and we shed light on the issues affecting the predictive value of these assays when translating their results into the clinical arena. In the last section of the review we briefly touched on the future trends and how they could increase the safety of gene therapy employing integrating vector technology to take it to the next level.
Export Options
About this article
Cite this article as:
Rothe Michael, Schambach Axel and Biasco Luca, Safety of Gene Therapy: New Insights to a Puzzling Case, Current Gene Therapy 2014; 14 (6) . https://dx.doi.org/10.2174/1566523214666140918110905
DOI https://dx.doi.org/10.2174/1566523214666140918110905 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Data Tagging in Medical Images: A Survey of the State-of-Art
Current Medical Imaging Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Magnetic Resonance Imaging of Nasopharyngeal Adenoid Hypertrophy in Children Following Bone Marrow Transplantation
Current Medical Imaging Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Tubulin-based Structure-affinity Relationships for Antimitotic Vinca Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers